Drug Topics June 18, 2024
Lauren Biscaldi, MS, Managing Editor

The vaccine covers 8 serotypes not currently covered by any FDA-approved pneumococcal vaccines.

The FDA has approved Merck’s Capvaxive (V116), Merck’s pneumococcal 21-valent conjugate vaccine, for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults aged 18 years and older.1

Capvaxive specifically targets the serotypes responsible for a majority of cases of invasive pneumococcal disease. It is approved for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B, as well as for active immunization for the prevention of pneumonia caused by S pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
‘He needs to do much more’: RFK Jr.'s measles response under scrutiny
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled

Share This Article